Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Am J Mens Health
2017 Jan 01;111:126-133. doi: 10.1177/1557988315602961.
Show Gene links
Show Anatomy links
Steroid Hormone Receptors as Potential Mediators of the Clinical Effects of Dutasteride: A Prospective, Randomized, Double-Blind Study.
Alonso JCC
,
Reis LO
,
Garcia PV
,
Ferreira U
,
Matheus WE
,
Simões FA
,
Rejowski RF
,
Alonso-Vale MIC
,
Fávaro WJ
.
???displayArticle.abstract???
This study characterizes the clinical and morphofunctional effects of a 5α-reductase inhibitor on steroid hormone receptors in normal human prostate tissue, as potential mediators of the clinical effects of dutasteride. This work was a prospective, double-blind, and randomized study that evaluated 49 men aged between 45 and 70 years, with no alterations in a digital rectal examination and prostate-specific antigen measurements between 2.5 and 4.0 ng/mL. These patients underwent prostate biopsy guided by transretal ultrasound with prostate neoplasia being ruled out, and the patients were divided into two groups, with one group receiving dutasteride ( n = 25) and one group receiving a placebo ( n = 24). The patients were clinically assessed each quarter, and at the end of 12 months they underwent new laboratory tests, prostate rebiopsy, and histopathological, immunohistochemical and clinical analyses. The estrogen receptor-beta (ERβ) and androgen receptor immunoreactivities were higher, and the proliferation/apoptotic ratio was significantly lower with predominance of the apoptotic process, followed by a significant reduction in the prostate volume and the total serum prostate-specific antigen levels in the dutasteride group when compared with the placebo group, with a clear supremacy of ERβ. There were no significant variations in the serum estrogen and testosterone levels, in the body mass index, or in the ERα immunoreactivities in the dutasteride and placebo groups. The results demonstrated the importance of the ERβ pathway in the activation mechanisms of apoptosis, exerting a protective effect in the normal prostate, indicating that this receptor might be an important mediator of the clinical effects of dutasteride.
Andriole,
Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.
2004, Pubmed
Andriole,
Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.
2004,
Pubmed
Brodie,
Aromatase in the normal breast and breast cancer.
1997,
Pubmed
Cunha,
It's not my fault, blame it on my microenvironment.
2002,
Pubmed
Ellem,
Aromatase and regulating the estrogen:androgen ratio in the prostate gland.
2010,
Pubmed
Fávaro,
Periacinar retraction clefting in nonneoplastic and neoplastic prostatic glands: artifact or molecular involvement.
2012,
Pubmed
Huggins,
Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.
2002,
Pubmed
Imamov,
Estrogen receptor beta in prostate cancer.
2004,
Pubmed
Klotz,
Canadian Consensus Conference: The FDA decision on the use of 5ARIs.
2012,
Pubmed
Leav,
Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma.
2001,
Pubmed
Marker,
Hormonal, cellular, and molecular control of prostatic development.
2003,
Pubmed
McPherson,
Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia.
2007,
Pubmed
Oliveira,
5alpha-Androstane-3beta,17beta-diol (3beta-diol), an estrogenic metabolite of 5alpha-dihydrotestosterone, is a potent modulator of estrogen receptor ERbeta expression in the ventral prostrate of adult rats.
2007,
Pubmed
Prins,
Neonatal estrogen exposure up-regulates estrogen receptor expression in the developing and adult rat prostate lobes.
1997,
Pubmed
Prins,
Androgen receptor localization in different cell types of the adult rat prostate.
1991,
Pubmed
Prins,
Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: studies with alphaERKO and betaERKO mice.
2001,
Pubmed
Pylkkänen,
Prostatic dysplasia associated with increased expression of c-myc in neonatally estrogenized mice.
1993,
Pubmed
Reis,
Variations of serum testosterone levels in prostate cancer patients under LH-releasing hormone therapy: an open question.
2012,
Pubmed
Reis,
Diethylstilbestrol 1 mg in the Treatment of Acute Urinary Retention due to Prostatic Obstruction in the Elderly: A Preliminary Study.
2014,
Pubmed
Reis,
Correlation Between Testosterone and PSA Kinetics in Metastatic Prostate Cancer Patients Treated With Diverse Chemical Castrations.
2015,
Pubmed
Reis,
Digital rectal examination standardization for inexperienced hands: teaching medical students.
2013,
Pubmed
Reis,
Old issues and new perspectives on prostate cancer hormonal therapy: the molecular substratum.
2012,
Pubmed
Risbridger,
Evidence that epithelial and mesenchymal estrogen receptor-alpha mediates effects of estrogen on prostatic epithelium.
2001,
Pubmed
Rosa-Ribeiro,
Transcription factors involved in prostate gland adaptation to androgen deprivation.
2014,
Pubmed
Rove,
Maximal testosterone suppression in prostate cancer--free vs total testosterone.
2014,
Pubmed
Shapiro,
Immunolocalization of estrogen receptor alpha and beta in human fetal prostate.
2005,
Pubmed
Thompson,
The influence of finasteride on the development of prostate cancer.
2003,
Pubmed
Untergasser,
Benign prostatic hyperplasia: age-related tissue-remodeling.
2005,
Pubmed
Watanabe,
Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies.
1995,
Pubmed
